Positive Linear Growth and Bone Responses to Growth Hormone Treatment in Children With Types III and IV Osteogenesis Imperfecta: High Predictive Value of the Carboxyterminal Propeptide of Type I Procollagen
暂无分享,去创建一个
George P Chrousos | Elizabeth Hopkins | F. Glorieux | G. Chrousos | C. Gundberg | J. Marini | Francis H Glorieux | E. Hopkins | Joan C Marini | James C Reynolds | Caren M Gundberg | C Michael Reing | J. C. Reynolds | C. M. Reing
[1] F. Diamond,et al. 6 Growth hormone neurosecretory dysfunction , 1986 .
[2] R. García-mayor,et al. Serum Insulin-Like Growth Factor (IGF) Binding Protein-3 and IGF-I Levels during Childhood and Adolescence. A Cross-Sectional Study , 1995, Pediatric Research.
[3] G. Saggese,et al. Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1 st year of life to adulthood and in metabolic bone diseases , 1992, European Journal of Pediatrics.
[4] J. R. Bowen,et al. Normative data for iliac bone histomorphometry in growing children. , 1992, Bone.
[5] G. Saggese,et al. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. , 1993, The Journal of pediatrics.
[6] J. Risteli,et al. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. , 1990, Clinical chemistry.
[7] D. Sillence,et al. Genetic heterogeneity in osteogenesis imperfecta. , 1979, Journal of medical genetics.
[8] F. Diamond,et al. Growth hormone neurosecretory dysfunction. , 2020, Clinics in endocrinology and metabolism.
[9] L. Tatò,et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. , 1996, The Journal of pediatrics.
[10] M. Knip,et al. Collagen metabolites in the prediction of response to GH therapy in short children. , 1997, European journal of endocrinology.
[11] F. Glorieux,et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. , 1998, The New England journal of medicine.
[12] T. Stijnen,et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. , 1999, The Journal of clinical endocrinology and metabolism.
[13] T. Nam,et al. Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children. , 1993, The Journal of clinical endocrinology and metabolism.
[14] E. Schönau,et al. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth‐promoting treatments in short normal children , 1996, Clinical endocrinology.
[15] S. Kanzaki,et al. Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype. , 1998, European journal of endocrinology.
[16] S. Kanzaki,et al. Molecular defects in achondroplasia and the effects of growth hormone treatment , 1999, Acta paediatrica (Oslo, Norway : 1992). Supplement.
[17] P. Esposito,et al. Osteogenesis Imperfecta. , 1928, Proceedings of the Royal Society of Medicine.
[18] F. Glorieux,et al. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. , 2000, Bone.
[19] D. Cole,et al. Serum osteocalcin concentrations in children with metabolic bone disease. , 1985, The Journal of pediatrics.
[20] G. Chrousos,et al. Endocrine aspects of growth deficiency in OI. , 1995, Connective tissue research.
[21] M. Drezner,et al. Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] G. Chrousos,et al. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. , 1993, American journal of medical genetics.
[23] F. Glorieux,et al. Structural and cellular changes during bone growth in healthy children. , 2000, Bone.
[24] P. Hindmarsh,et al. Serum Concentrations of the Type I and III Procollagen Propeptides as Biochemical Markers of Growth Velocity in Healthy Infants and Children and in Children with Growth Disorders , 1991, Pediatric Research.
[25] P. Robey,et al. Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] J. Kopp,et al. Osteogenesis imperfecta: Changes in noncollagenous proteins in bone , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] G. Saggese,et al. Twenty-four-Hour Osteocalcin, Carboxyterminal Propeptide of Type I Procollagen, and Aminoterminal Propeptide of Type III Procollagen Rhythms in Normal and Growth-Retarded Children , 1994, Pediatric Research.
[28] Z. Hochberg,et al. Final height in young women with Turner syndrome after GH therapy: an open controlled study. , 1999, European journal of endocrinology.
[29] P. Robey,et al. Human bone cells in vitro. , 1985, Calcified tissue international.
[30] G. Chrousos,et al. The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. , 1993, The Journal of clinical endocrinology and metabolism.
[31] W. Mendelson,et al. Growth hormone neurosecretory dysfunction. A treatable cause of short stature. , 1984, JAMA.